There are not enough studies on whether pills are as effective in improving or eliminating symptoms as parenteral treatment
Sleep 43 , zsz194 (2020)
This system rated cartilage structural integrity from 0, defined as normal to 6, defined as complete disorganization, and assessed cellularity from 0, defined as normal, to 3, defined as hypocellularity, for a total possible score of 0 to 9
This IV aims to replenish essential nutrients and reduce inflammation
Triple-hormone-receptor agonist Retatrutide for obesity: Phase 2 trial (48-week study, up to 24% weight loss) American Diabetes Association (2023) ADA Press Release: Novel agent Retatrutide results in substantial weight reduction (83rd Scientific Sessions, Phase 2 data) ADA Meeting News (2023) Phase 2 trial results: benefits of Retatrutide in obesity, type 2 diabetes, NASH (83rd ADA Scientific Sessions coverage) ClinicalTrials.gov Study of Retatrutide (LY3437943) in adults with obesity (NCT04881760
